We serve Chemical Name:N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine CAS:56849-88-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine
CAS.NO:56849-88-8
Synonyms:N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine
Molecular Formula:C8H17NSi
Molecular Weight:155.31300
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:85ºC
Density:0.774
Index of Refraction:n20/D 1.4383
PSA:3.24000
Exact Mass:155.11300
LogP:1.42880
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1993
Packing Group:
Contact us for information like N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine Use and application,N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine technical grade,usp/ep/jp grade.
Related News: In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine manufacturer Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine supplier Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management, Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said. N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine vendor The CTSuccess service uses Catalent��s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics. N,N-dimethyl-3-trimethylsilylprop-2-yn-1-amine factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.
